{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"The maximum tolerated dose of carfilzomib that can be safely combined with high dose melphalan as conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma meeting eligibility criteria.","groups":[{"description":"All patients who receive transplant in the phase 1 of the study","id":"OG000","title":"Patients Undergoing Transplantation"}],"paramType":"NUMBER","populationDescription":"Patients who underwent transplantation during phase 1","reportingStatus":"POSTED","timeFrame":"Up to 4 1/2 months","title":"Maximum Tolerated Dose (MTD) of Carfilzomib Plus Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Relapsed Multiple Myeloma(MM) [Phase I Portion of Study]","type":"PRIMARY","unitOfMeasure":"mg/m2"}